Fig. 3.

Association of anti-SARS-CoV-2 antibody response of COVID-19 patients with clinical severity during SARS-CoV-2 infection. Antibody profiles of COVID-19 patients at timepoint of median 23 days post-illness onset (pio, n = 66) against significant IgG peptides under different clinical measures of (a) disease severity, (b) pneumonia, and (c) intensive care unit (ICU) admission and oxygen supply requirement. Samples in (a) were classified based on severity with green denoting mild (clinical severity 0; n = 28), blue denoting moderate (clinical severity 1; n = 22), and red denoting severe (clinical severity 2; n = 16). Data are presented as mean ± SD of two independent experiments. Negative and positive observations in (b-c) are denoted as - and +, respectively. Statistical analysis was carried out using Kruskal-Wallis tests, followed by post hoc Dunn's multiple comparison tests. (**P<0•01, ***P<0•001).